Pembrolizumab for Previously Untreated Patients with Advanced Non-small-cell Lung Cancer and Preexisting Interstitial Lung Disease

OBJECTIVE: Pembrolizumab has benefited patients with advanced non-small-cell lung cancer (NSCLC) with a programmed death-ligand (PD-L)1 high expression, but little information is available regarding its safety for patients with interstitial lung disease (ILD). The aim of this study was to assess the...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Intern Med
Glavni autori: Fujita, Tetsuo, Kuroki, Tsuguko, Hayama, Nami, Shiraishi, Yuka, Amano, Hiroyuki, Nakamura, Makoto, Hirano, Satoshi, Tabeta, Hiroshi, Nakamura, Sukeyuki
Format: Artigo
Jezik:Inglês
Izdano: The Japanese Society of Internal Medicine 2020
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7492129/
https://ncbi.nlm.nih.gov/pubmed/32389949
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.4552-20
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items